Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Jorge Castillo, MD Dana-Farber Cancer Institute, Boston, MA, provides an update on phase II trials of venetoclax therapy as a treatment for Waldenström’s Macroglobulinemia patients, alongside an overview of the disease biology. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.